Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 2/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.48 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.46 |
| ▸ | PI4KA | P42356 | 4/20 | 0.43 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.43 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.43 |
| ▸ | GMPS | P49915 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.43 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.43 |
| ▸ | GAPDH | P04406 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | STAT6 | P42226 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23647916 | 0.90 | SLC28A1 (0.55) | SLC28A1ADORA2AADORA3PI4KAPI4K2B | |
| SCHEMBL29786250 | 0.89 | SLC28A1 (0.54) | SLC28A1ADORA2AADORA3PI4KAPI4K2B | |
| SCHEMBL25222252 | 0.89 | SLC28A1 (0.54) | SLC28A1ADORA2AADORA3PI4KAPI4K2B | |
| SCHEMBL1550156 | 0.85 | ADORA3 (0.49) | SLC28A1ADORA2AADORA3PI4KAPI4K2B | |
| SCHEMBL28250706 | 0.84 | ADORA3 (0.52) | SLC28A1ADORA2AADORA3PI4KAPI4K2B | |
| SCHEMBL5318774 | 0.82 | SLC28A1 (0.54) | SLC28A1ADORA2AADORA3PI4KAPI4K2B | |
| SCHEMBL28748817 | 0.82 | SLC28A1 (0.54) | SLC28A1ADORA2AADORA3PI4KAPI4K2B | |
| SCHEMBL28791555 | 0.82 | P2RX1 (0.51) | SMN1; SMN2 | |
| SCHEMBL9120616 | 0.82 | SLC28A1 (0.49) | SLC28A1ADORA2AADORA3EHMT1PI4KA | |
| SCHEMBL7868209 | 0.81 | SLC28A1 (0.47) | SLC28A1ADORA2AADORA3EHMT1PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1032405-A4 | ANTIMUTAGENIC COMPOSITIONS FOR TREATMENT AND PREVENTION OF PHOTODAMAGE TO SKIN | WELLSTAT THERAPEUTICS CORP (US) | 2007-05-02 | — | — | EP | claimed |
| US-20020006913-A1 | ANTIMUTAGENIC COMPOSITIONS FOR TREATMENT AND PREVENTION OF PHOTODAMAGE TO SKIN | PRO-NEURON, INC. | 2002-01-17 | — | — | US | claimed |
| US-20010044421-A1 | Administering to skin a composition containing deoxyribonucleosides in concentrations sufficient to enhance DNA repair or reduce mutation frequency in a vehicle capable of delivering deoxyribonucleosides to skin cells | PRO-NEURON, INC. | 2001-11-22 | — | — | US | claimed |
| US-20010044419-A1 | Antimutagenic compositions for treatment and prevention of photodamage to skin | PRO-NEURON, INC. | 2001-11-22 | — | — | US | claimed |
| EP-1032405-A1 | ANTIMUTAGENIC COMPOSITIONS FOR TREATMENT AND PREVENTION OF PHOTODAMAGE TO SKIN | PRO-NEURON, INC. (US) | 2000-09-06 | — | — | EP | claimed |
| WO-1999022741-A1 | ANTIMUTAGENIC COMPOSITIONS FOR TREATMENT AND PREVENTION OF PHOTODAMAGE TO SKIN | PRO-NEURON, INC. (US) | 1999-05-14 | — | — | WO | claimed |
| US-20040192635-A1 | Acyl deoxyribonucleoside derivatives and uses thereof | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-09-30 | — | — | US | disclosed |
| US-6743782-B1 | ACYL DERIVATIVE OF 2'-DEOXYADENOSINE; TREATING OR PREVENTING RADIATION, MUTAGEN AND SUNLIGHT-INDUCED CELLULAR DAMAGE, IMPROVING WOUND HEALING AND TISSUE REPAIR, AMELIORATING THE EFFECTS OF AGING; ENHANCE BIOAVAILABILITY | WELLSTAT THERAPEUTICS CORPORATION | 2004-06-01 | — | — | US | disclosed |
| EP-1272501-A1 | PROCESS FOR THE PREPARATION OF PHOSPHOROTHIOATE TRIESTERS | Avecia Limited (GB) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001064702-A1 | PROCESS FOR THE PREPARATION OF PHOSPHOROTHIOATE TRIESTERS | AVECIA LIMITED (GB) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192635-A1 | Acyl deoxyribonucleoside derivatives and uses thereof | UNG, OGG1, NQO1 | SLC28A1 2678/4885ADORA2A 563/4885ADORA3 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.